ASRT's President and COO Sells Shares Amidst Insider Moves

Paul Schwichtenberg, President and COO of ASRT, sold 78,811 shares of the company on June 16, 2026. This transaction is part of recent insider activity at ASRT, where several executives have been adjusting their holdings. Schwichtenberg's sale did not take place under a pre-planned trading program.

Other Institutional Activity in ASRT

Nantahala Capital Management grew its holdings in ASRT by 105,000 shares, bringing its total to 692,335 shares valued at approximately $13.2 million. Vanguard Capital Management also added to its position, acquiring 268,952 shares worth about $5.1 million. On the other hand, Opaleye Management reduced its stake by 19,293 shares, leaving it with 265,707 shares valued at around $5.1 million. Renaissance Technologies increased its holding by 37,902 shares, totaling 228,599 shares valued at $4.4 million. Meanwhile, Edgewood Management and BlackRock made minor adjustments to their positions, with Edgewood slightly reducing and BlackRock slightly increasing their respective holdings.

ASRT Stock Snapshot

Shares of ASRT traded at $23.5 recently. While specific financial ratios and moving averages are not provided, the stock's activity includes notable insider and institutional transactions, reflecting ongoing interest and adjustments by key stakeholders.

Insider Buying and Selling at ASRT

On June 16, 2026, several insiders at ASRT engaged in transactions. Kirk Sigurd sold 12,017 shares, David Matthew Stark sold 11,420 shares, and Ajay Patel, EVP and CFO, sold 72,051 shares. Additionally, William McKee sold 27,936 shares, and Sravan Kumar Emany sold 23,855 shares. These sales were not part of any planned trading programs.

Analysts Set New Price Targets

On May 13, 2026, Lake Street maintained its 'hold' rating for ASRT with a price target of $23.5. HC Wainwright & Co. also maintained a 'hold' rating with a target of $21.8 as of May 5, 2026. Earlier in April, both firms downgraded their ratings to 'hold' with a target of $18.0.

About ASRT

ASRT operates in the healthcare industry, focusing on developing and commercializing pharmaceutical products. The company is headquartered in the United States and is led by a team of experienced executives committed to advancing innovative treatments for patients.

Bottom Line

The recent insider sales at ASRT, including those by President and COO Paul Schwichtenberg, highlight significant activity within the company. Investors often track such moves for potential insights into company leadership's confidence. However, it's important to remember that these transactions are disclosed after they occur and may not reflect current positions or future intentions.